Research advances in lysosomal transmembrane protein 175 in Parkinson disease
10.19845/j.cnki.zfysjjbzz.2025.0024
- VernacularTitle:溶酶体跨膜蛋白175在帕金森病中的研究进展
- Author:
Fangli REN
1
;
Xu ZHOU
1
;
Xinling YANG
2
Author Information
1. 新疆医科大学第二附属医院，新疆 乌鲁木齐 830063
2. 新疆医科大学，新疆 乌鲁木齐 830017
- Publication Type:Journal Article
- Keywords:
Parkinson disease;
Transmembrane protein 175;
TMEM175 gene;
Lysosomal dysfunction;
α-synuclein
- MeSH:
Parkinson Disease
- From:
Journal of Apoplexy and Nervous Diseases
2025;42(2):121-125
- CountryChina
- Language:Chinese
-
Abstract:
Parkinson disease (PD) is a complex neurodegenerative disorder characterized by a variety of motor and non-motor symptoms. Many studies have shown that the transmembrane protein 175 (TMEM175) gene may be a potential target for the treatment of PD and other neurodegenerative disorders, but the specific pathogenic mechanism remains unclear. TMEM175 is a lysosomal protein-coding gene that encodes a lysosomal proton channel protein. This article reviews the research advances in the characterization of the TMEM175 gene and its encoded proteins, the clinical features of mutant PD, and related pathogenic mechanism. It is shown that the TMEM175 gene has an impact on the pathogenesis of PD, and patients with different mutation sites tend to have different ages of onset and clinical features. Compared with the patients without TMEM175 mutations, the patients with TMEM175 mutations tend to have an earlier age of onset, more severe motor symptoms, and more susceptibility to cognitive impairment and non-motor symptoms. This article systematically reviews the TMEM175 gene, in order to assist in the early diagnosis of PD and the discovery of new disease-modifying therapies and treatment strategies.
- Full text:2025071514140364450溶酶体跨膜蛋白175在帕金森病中的研究进展.pdf
